Schwab Charles Investment Management Inc. boosted its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 6.7% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 409,522 shares of the company’s stock after acquiring an additional 25,834 shares during the period. Schwab Charles Investment Management Inc.’s holdings in Neurocrine Biosciences were worth $31,775,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. The Manufacturers Life Insurance Company lifted its stake in Neurocrine Biosciences by 7.8% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 2,665 shares of the company’s stock valued at $123,000 after buying an additional 193 shares in the last quarter. Crow Point Partners LLC purchased a new stake in Neurocrine Biosciences in the 4th quarter valued at approximately $145,000. Comerica Bank purchased a new stake in Neurocrine Biosciences in the 3rd quarter valued at approximately $210,000. Ardsley Advisory Partners purchased a new stake in Neurocrine Biosciences in the 2nd quarter valued at approximately $230,000. Finally, Cubist Systematic Strategies LLC lifted its stake in Neurocrine Biosciences by 151.5% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 5,301 shares of the company’s stock valued at $244,000 after buying an additional 3,193 shares in the last quarter.

NBIX has been the topic of a number of recent research reports. Robert W. Baird reaffirmed a “buy” rating and issued a $84.00 target price on shares of Neurocrine Biosciences in a research note on Friday, November 3rd. Needham & Company LLC upped their target price on Neurocrine Biosciences to $95.00 and gave the company a “buy” rating in a research note on Tuesday, January 16th. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $76.00 target price on shares of Neurocrine Biosciences in a research note on Wednesday, October 25th. Oppenheimer set a $95.00 target price on Neurocrine Biosciences and gave the company a “buy” rating in a research note on Monday, January 15th. Finally, Deutsche Bank reaffirmed a “buy” rating and issued a $79.00 target price on shares of Neurocrine Biosciences in a research note on Thursday, November 2nd. One equities research analyst has rated the stock with a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the company. Neurocrine Biosciences presently has an average rating of “Buy” and a consensus price target of $84.13.

Neurocrine Biosciences, Inc. (NASDAQ NBIX) opened at $79.28 on Monday. The company has a quick ratio of 14.37, a current ratio of 14.38 and a debt-to-equity ratio of 1.05. The firm has a market capitalization of $7,020.00, a price-to-earnings ratio of -35.71, a price-to-earnings-growth ratio of 13.14 and a beta of 0.26. Neurocrine Biosciences, Inc. has a twelve month low of $39.21 and a twelve month high of $91.82.

In other news, insider Darin Lippoldt sold 9,900 shares of the company’s stock in a transaction on Wednesday, November 15th. The stock was sold at an average price of $73.05, for a total transaction of $723,195.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Kevin Charles Gorman sold 3,750 shares of the company’s stock in a transaction on Tuesday, January 16th. The stock was sold at an average price of $78.89, for a total value of $295,837.50. The disclosure for this sale can be found here. Insiders sold a total of 189,707 shares of company stock valued at $14,975,715 over the last quarter. 4.80% of the stock is currently owned by insiders.

TRADEMARK VIOLATION WARNING: “Schwab Charles Investment Management Inc. Buys 25,834 Shares of Neurocrine Biosciences, Inc. (NBIX)” was originally posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this piece on another domain, it was stolen and republished in violation of United States and international copyright laws. The correct version of this piece can be viewed at https://theolympiareport.com/2018/02/12/schwab-charles-investment-management-inc-buys-25834-shares-of-neurocrine-biosciences-inc-nbix.html.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.

Want to see what other hedge funds are holding NBIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neurocrine Biosciences, Inc. (NASDAQ:NBIX).

Institutional Ownership by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.